<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The prevalence of long-term oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy is rising </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment options for patients who have an <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> under oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy are limited, and clinical data on the risk of hemorrhagic transformation (HT) in this condition are scarce </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore aimed to establish a mouse model of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> occurring during oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy to assess the frequency and characteristics of HT </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: C57BL/6 mice (n=59) were pretreated with <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Untreated mice (n=32) served as controls </plain></SENT>
<SENT sid="5" pm="."><plain>We performed a 3-hour transient filament occlusion of the right middle cerebral artery </plain></SENT>
<SENT sid="6" pm="."><plain>In a first set of animals, ischemic lesion size and HT were evaluated macroscopically at 24 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>In a second set of mice, quantitative analysis of HT was performed at different time points after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and in animals with different international normalized ratio levels using a photometric <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> assay </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy at the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> led to HT in <z:hpo ids='HP_0000001'>all</z:hpo> anticoagulated mice, whereas only 14% of the control mice showed HT </plain></SENT>
<SENT sid="9" pm="."><plain>Mean HT blood volume 24 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was 0.3±0.4 μL in controls, 4.2±1.7 μL in mice anticoagulated to a mean international normalized ratio of 1.9±0.5 (P&lt;0.05 versus controls), and 5.2±2.7 μL in mice with an international normalized ratio of 2.9±0.9 (P&lt;0.001 versus controls) </plain></SENT>
<SENT sid="10" pm="."><plain>Anticoagulated mice euthanized at the time point of reperfusion had less HT than mice euthanized after 21 hours of reperfusion (1.6±0.5 μL versus 5.9±3.6 μL, P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: We present a mouse model of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> occurring during oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> pretreatment dramatically increases the risk of HT 24 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>Reperfusion injury seems to be a critical component in this condition </plain></SENT>
</text></document>